Ribonucleic Acid (RNA) Interference Technology Market Global Report 2026

The ribonucleic acid (RNA) interference technology market size has grown rapidly in recent years. It will grow from $4.67 billion in 2025 to $5.29 billion in 2026 at a compound annual growth rate (CAGR) of 13.2%. The growth in the historic period can be attributed to rising use of gene knockdown techniques in research laboratories, expansion of genomic sequencing capabilities, increasing funding for molecular biology research, early adoption of sirna-based experimental therapies, growth in academic-industry collaboration for gene function studies.

The ribonucleic acid (RNA) interference technology market size is expected to see rapid growth in the next few years. It will grow to $8.57 billion in 2030 at a compound annual growth rate (CAGR) of 12.8%. The growth in the forecast period can be attributed to increasing clinical approvals of rna-based therapeutics, growing demand for precision medicine and targeted gene silencing, advancements in delivery technologies improving in vivo efficiency, expansion of biotech pipelines focused on genetic diseases, rising investment in RNA interference drug discovery platforms. Major trends in the forecast period include expansion of RNA-based therapeutics targeting rare genetic disorders and oncology applications, increasing focus on off-target effect reduction and improved gene silencing accuracy in RNai systems, advancements in RNA stability enhancement and chemical modification of siRNA molecules, growing adoption of lipid-based and non-viral delivery systems for efficient intracellular RNA transport, rising integration of RNai platforms in functional genomics and high-throughput target validation pipelines.

The increasing demand for oncology therapeutics is expected to propel the growth of the ribonucleic acid (RNA) interference technology market going forward. Oncology therapeutics encompass medications and treatment strategies used to prevent, manage, and treat cancer by targeting malignant cells, controlling tumor progression, or limiting the spread of the disease. The demand for oncology therapeutics is rising due to the increasing global burden of cancer, which is fueling the need for advanced treatment options such as targeted therapies, immunotherapies, and personalized medicines to improve patient outcomes. RNA interference (RNAi) technology supports oncology therapeutics by enabling the precise silencing of cancer-associated genes involved in tumor progression, metastasis, and drug resistance. For instance, in May 2025, according to the National Cancer Institute, a US-based government agency, approximately 2,041,910 new cancer cases are projected to be diagnosed in the United States, with an estimated 618,120 deaths attributed to the disease. Therefore, the increasing demand for oncology therapeutics is driving the growth of the ribonucleic acid (RNA) interference technology market.

Major companies operating in the ribonucleic acid (RNA) interference technology market are focusing on developing advanced platforms, such as conditionally activated small interfering RNA (siRNA) molecules, to enhance cell-specific targeting, improve therapeutic effectiveness, and broaden the applications of RNA-based therapeutics. Conditionally activated siRNA (CASi) is an innovative RNA interference approach that activates gene-silencing activity only within targeted cells, enabling more precise and controlled therapeutic interventions. For instance, in March 2023, Switch Therapeutics, a US-based biotechnology company, introduced its proprietary CASi platform following a $52 million Series A financing round. The platform combines nucleic acid nanotechnology with RNA interference science to facilitate cell-selective gene knockdown, efficient self-delivery, sustained therapeutic activity, and targeted activation of siRNA molecules in specific cell types. The company plans to use the funding to advance its lead central nervous system (CNS) disease program and accelerate the development of next-generation RNAi therapies.

In June 2024, GSK plc, a UK-based pharmaceutical company, acquired Elsie Biotechnologies Inc. and its oligonucleotide discovery platform for $50 million. Through this acquisition, GSK aimed to strengthen its oligonucleotide and RNA interference technology capabilities by enhancing its platform for gene expression modulation and accelerating the development of advanced RNA-based therapeutics and precision medicine applications. Elsie Biotechnologies is a US-based biotechnology company that operates within the broader ribonucleic acid (RNA) interference (RNAi) technology ecosystem through its expertise in oligonucleotide therapeutics.

Major companies operating in the ribonucleic acid (RNA) interference technology market report are Roche Diagnostics International AG, Thermo Fisher Scientific Inc., Merck KGaA, Agilent Technologies Inc., Silence Therapeutics plc, Revvity Inc., QIAGEN N.V., Takara Bio Inc., Arrowhead Pharmaceuticals Inc., Bioneer Corporation, Alnylam Pharmaceuticals Inc., Novo Nordisk A/S, Integrated DNA Technologies, GeneCopoeia Inc.

North America was the dominating region in the ribonucleic acid (RNA) interference technology market in 2025. Asia-Pacific is expected to be the rapidly growing region in the forecast period. The regions covered in the ribonucleic acid (RNA) interference technology market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the ribonucleic acid (RNA) interference technology market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

This product will be delivered within 3-5 business days.